Group 1 - The company Zhejiang Jiuzhou Pharmaceutical Co., Ltd. announced that its subsidiary Zhejiang Jiuzhou Biopharmaceutical Co., Ltd. received a drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration [1][2] - The drug is classified as a chemical drug of category 4, with a specification of 50mg and a registration number valid until June 23, 2030 [1] - The total sales of Sildenafil Citrate tablets in the domestic medical and retail market reached 5.217 billion RMB in 2023 [2] Group 2 - The approval of the drug registration certificate enhances the company's product pipeline and market competitiveness [2] - The company has invested approximately 13.52 million RMB in the research and development of Sildenafil Citrate Orally Disintegrating Tablets [2]

Group 1: Company Announcements - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international brand image [1] - Saisir reported June sales of 46,086 new energy vehicles, a year-on-year increase of 4.44%, with a total of 172,100 units sold in the first half of the year, down 14.35% year-on-year [1] - Hangzhou High-tech announced a change in controlling shareholder to Jirong Weiye, with stock resuming trading on July 2, 2025 [1] Group 2: Financial Performance - Guomai Technology expects a net profit of 125 million to 156 million yuan for the first half of 2025, a year-on-year increase of 60.52% to 100.33% [2] - Kid King anticipates a net profit of 120 million to 160 million yuan for the first half of 2025, representing a year-on-year growth of 50% to 100% [2] - Mould Technology received a project from a well-known North American electric vehicle company, with expected total sales of 1.236 billion yuan over five years [3] Group 3: Regulatory and Compliance - *ST Yuancheng is under investigation by the China Securities Regulatory Commission for suspected false disclosures in financial reports [4] - The company received a notice of investigation on July 1, 2025, which may lead to significant penalties and potential delisting [4] Group 4: Market Activity - Changcheng Military Industry's stock has experienced significant volatility, with a cumulative price deviation exceeding 20% over three trading days, indicating potential irrational speculation [5] - Anglikang has only one innovative drug project, ALK-N001, currently in Phase I clinical trials, highlighting the long and uncertain nature of drug development [6] Group 5: Sales and Contracts - Beiqi Blue Valley's subsidiary reported a 139.73% year-on-year increase in sales for the first half of the year [7] - Dong'an Power's engine sales in June increased by 82.79% year-on-year [7] - Pudong Construction's subsidiary won multiple major projects with a total bid amount of 1.964 billion yuan [7]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：603456 证券简称：九洲药业 公告编号：2025-039 剂型：片剂 规格：50mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 浙江九洲药业股份有限公司 关于控股子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江九洲药业股份有限公司（以下简称"公司"）控股子公司浙江九 洲生物医药有限公司（以下简称"九洲生物"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的枸橼酸西地那非口崩片的《药品注册证书》，具 体情况如下： 一、药品的基本情况 药品名称：枸橼酸西地那非口崩片 批准文号：国药准字 H20254619 批准文号有效期：至 2030 年 6 月 23 日 上市许可持有人：浙江九洲生物医药有限公司 截至目前，公司已在枸橼酸西地那非口崩片累计研发投入约为人民币 1,352 万元。 上市许可持有人地址：浙江省杭州市经济技术开发区下沙街道乔新路 500 号和科科技中心 2 幢一层 103 室 生产单位：浙江四维医药科技有限公司 生产地址：浙江省台州市椒江 ...

Core Viewpoint - The company, Jiuzhou Pharmaceutical, announced that its subsidiary, Zhejiang Jiuzhou Biopharmaceutical Co., Ltd., has received the drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration of China [1] Group 1: Company Developments - The drug is an iterative formulation of Sildenafil developed by Pfizer, which was approved for import in China in 2019 [1] - Jiuzhou Pharmaceutical has invested approximately 13.52 million RMB in the research and development of Sildenafil Citrate Orally Disintegrating Tablets [1] - The acquisition of the drug registration certificate enhances the company's product pipeline and market competitiveness, although it is not expected to have a significant impact on the company's performance in the short term [1] Group 2: Market Context - The total sales revenue (end-user price) of Sildenafil Citrate tablets in the domestic medical and retail market reached 5.217 billion RMB in 2023 [1] - Major competitors in the market that have also received the drug registration certificate include Sichuan Kelun Pharmaceutical Co., Ltd. and Guangdong Tianenkang Pharmaceutical Co., Ltd. [1]

Core Viewpoint - Zhejiang Jiuzhou Pharmaceutical Co., Ltd. has decided to change the purpose of its share repurchase plan from "for future implementation of equity incentive plans" to "for cancellation and reduction of registered capital" by canceling 5,789,800 shares from its repurchased stock account [1][3]. Group 1: Share Repurchase Plan - The company proposed a share repurchase plan on December 26, 2023, to buy back shares using its own funds through centralized bidding, initially intended for equity incentive or employee stock ownership plans [1]. - On January 4, 2024, the board approved the repurchase plan, allowing the company to buy back shares at a price not exceeding RMB 36 per share, with a total repurchase amount between RMB 50 million and RMB 100 million within 12 months [2]. - The actual repurchase was completed, with a total of 5,789,800 shares bought back, accounting for 0.65% of the company's total share capital, with a total expenditure of approximately RMB 99.89 million [2][3]. Group 2: Share Cancellation Details - The company plans to cancel the repurchased shares and reduce its registered capital accordingly, with the cancellation process having been approved in board meetings held on April 10 and May 8, 2025 [3]. - The cancellation of 5,789,800 shares will reduce the total share capital from 895,235,828 shares to 889,446,028 shares, maintaining the same percentage of unlimited sale shares at 100% [5]. - The company has completed the necessary creditor notification procedures, and no claims or guarantees were requested by creditors during the public notice period [3].

证券代码：603456 证券简称：九洲药业 公告编号：2025-038 浙江九洲药业股份有限公司 关于注销部分已回购股份的实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：浙江九洲药业股份有限公司（以下简称"公司"）分别于 2025 年 4 月 10 日、5 月 8 日召开第八届董事会第十三次会议、2024 年年度股东 大会，审议通过《关于变更回购股份用途并注销的议案》，同意公司将 2024 年股 份回购方案用途由"用于后续实施股权激励计划"变更为"用于注销并减少公司 注册资本"，即对回购专用证券账户中 2024 年股份回购方案的 5,789,800 股库存 股进行注销并相应减少注册资本。 本次注销股份的有关情况 | 回购专用证券账户 | 本次注销 | 注销日期 | | | --- | --- | --- | --- | | 股份数量（股） | 股份数量（股） | | | | 13,525,800 | 5,789,800 2025 | 年 月 6 | 日 26 | 公司分别于 2025 年 ...

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于 浙江九洲药业股份有限公司 法律意见书 编号：TCYJS2025H0852 号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司（以 下简称"九洲药业"或"公司"）的委托，就公司 2024 年度利润分配方案所涉及 的差异化权益分派（以下简称"本次差异化权益分派"）相关事宜，根据《中华人 民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股份回购规则（2025 修订）》（以下简称 "《回购规则》"）和《上海证券交易所上市公司自律监管指引第 7 号——回购股 份（2025 年 3 月修订）》（以下简称"《自律监管指引第 7 号》"）等有关法律、 法规和有关规范性文件，出具本法律意见书。 第一部分 声明事项 为出具本法律意见书，本所及本所律师声明如下： 一、为出具本法律意见书 ...

Core Points - The company announced a cash dividend of 0.30 CNY per share for A shares [1][5] - The dividend distribution plan was approved at the annual general meeting on May 8, 2025 [2][3] - The total cash dividend distribution amounts to approximately 264.51 million CNY, representing 60.33% of the net profit attributable to shareholders for the fiscal year 2024 [2][3] Dividend Distribution Details - The record date for the dividend is June 18, 2025, with the last trading day on June 19, 2025, and the ex-dividend date also on June 19, 2025 [1][4] - The total share capital as of April 10, 2025, is 895,235,828 shares, with 9,368,500 shares in the repurchase account excluded from the dividend distribution [2][3] - The cash dividend will be distributed to shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [5][6] Taxation Information - Individual shareholders will not have personal income tax withheld at the time of dividend distribution, with a net cash dividend of 0.30 CNY per share [6][7] - For individual shareholders holding shares for less than one month, the effective tax rate on dividend income is 20%, while for those holding between one month and one year, it is 10% [6][7] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in a net cash dividend of 0.27 CNY per share [6][7]

浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2024 年度差异化权益分派事项的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 0 法律意见书 浙江天册律师事务所 关于 浙江九洲药业股份有限公司 2024 年度差异化权益分派事项的 法律意见书 编号：TCYJS2025H0852 号 致：浙江九洲药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江九洲药业股份有限公司（以 下简称"九洲药业"或"公司"）的委托，就公司 2024 年度利润分配方案所涉及 的差异化权益分派（以下简称"本次差异化权益分派"）相关事宜，根据《中华人 民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股份回购规则（2025 修订）》（以下简称 "《回购规则》"）和《上海证券交易所上市公司自律监管指引第 7 号——回购股 份（2025 年 3 月修订）》（以下简称"《自律监管指引第 7 号》"）等有关法律、 法规和有关规范性文件，出具本法律意见书。 第一部分 声 ...